Members of the Department of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai (ISMMS) engage in critically important research in order to understand and improve treatment, procedures, and outcomes for patients.
Mitral surgeons at Mount Sinai are also leading clinical trials in conjunction with the Mount Sinai Center for Medical Devices (CMeD) that may one day revolutionize less invasive mitral valve repair and replacement.
Mitral Valve Research
Our Mitral Valve Repair Reference Center at The Mount Sinai Hospital is one of the most advanced in the country. Our faculty keeps the Center at the forefront of research in assessment and treatment of this disease. We investigate ischemic mitral valve disease, outcomes related to mitral valve repair, and the impact of tricuspid valve repair at the time of mitral surgery. In addition to authoring hundreds of publications, our group has published landmark editorials. We publish articles on mitral valve repair and research, with key outcomes showing excellent results after mitral and tricuspid valve repair, including the largest series of Barlow’s valve patients in the literature.
Beating Heart Mitral Valve Repair
Our physicians conduct clinical research utilizing novel medical devices. Dr. Adams is the national co-principal investigator of the NeoChord FDA pivotal trial, which is establishing the effectiveness of closed beating heart mitral valve repair through a mini-thoracotomy compared with open surgery. In November 2016, Dr. Adams and his team performed the first NeoChord repair procedure in the United States. This trial will expand to more than 20 centers in the nation and will be ongoing for a few years.
Transcatheter Mitral Valve Replacement (TMVR)
Dr. Adams also serves as the national co-principal investigator of the Medtronic Intrepid FDA pivotal trial, which will establish the effectiveness of transcatheter closed beating heart mitral valve replacement in patients with increased risk for conventional or surgical mitral valve replacement. During its course, this trial is anticipated to involve more than 40 centers, including The Mount Sinai Hospital.
Transcatheter Aortic Valve Replacement (TAVR)
Dr. Adams serves as the national co-primary investigator for the CoreValve United States FDA Pivotal Trial, which has helped establish the safety and efficacy of transcatheter aortic valve replacement as an alternative to open surgery. He first authored the pivotal trial results in high-risk patients in the New England Journal of Medicine, and today patients at Mount Sinai have access to the very latest treatments for aortic valve disease, both by surgical and interventional approaches.